OA11039A - Antimalarial compositions containing cis-fused cyclopenteno-1,2,4-trioxane derivatives - Google Patents

Antimalarial compositions containing cis-fused cyclopenteno-1,2,4-trioxane derivatives Download PDF

Info

Publication number
OA11039A
OA11039A OA9900089A OA9900089A OA11039A OA 11039 A OA11039 A OA 11039A OA 9900089 A OA9900089 A OA 9900089A OA 9900089 A OA9900089 A OA 9900089A OA 11039 A OA11039 A OA 11039A
Authority
OA
OAPI
Prior art keywords
compound
trioxane
component
drug
combination
Prior art date
Application number
OA9900089A
Other languages
English (en)
Inventor
Wallace Peters
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of OA11039A publication Critical patent/OA11039A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA9900089A 1996-10-28 1999-04-28 Antimalarial compositions containing cis-fused cyclopenteno-1,2,4-trioxane derivatives OA11039A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622427.4A GB9622427D0 (en) 1996-10-28 1996-10-28 Antimalarial drugs

Publications (1)

Publication Number Publication Date
OA11039A true OA11039A (en) 2003-03-07

Family

ID=10802068

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900089A OA11039A (en) 1996-10-28 1999-04-28 Antimalarial compositions containing cis-fused cyclopenteno-1,2,4-trioxane derivatives

Country Status (15)

Country Link
US (1) US5834505A (de)
EP (1) EP0938306B1 (de)
JP (1) JP2001507672A (de)
AT (1) ATE224709T1 (de)
AU (1) AU738885B2 (de)
CA (1) CA2270138A1 (de)
DE (1) DE69715895T2 (de)
DK (1) DK0938306T3 (de)
ES (1) ES2183146T3 (de)
GB (1) GB9622427D0 (de)
IL (1) IL129635A (de)
NZ (1) NZ335451A (de)
OA (1) OA11039A (de)
PT (1) PT938306E (de)
WO (1) WO1998018462A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191696B (de) * 1999-02-12 2003-12-20 Council Scient Ind Res
EP1261340B1 (de) 1999-07-13 2009-05-13 Alpha Research Group, LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
EP2200611A4 (de) 2007-09-14 2010-09-22 Biogen Idec Inc Zusammensetzungen und verfahren zur behandlung von progressiver multifokaler leukoenzephalopathie (pml)
US20180055835A1 (en) 2016-08-25 2018-03-01 Immune Therapeutics Inc. Method for Treating And Preventing Protozoal Infections
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672734A5 (de) * 1987-04-03 1989-12-29 Charles W Jefford
IN166154B (de) * 1987-05-08 1990-03-24 Hoechst India
SU1689336A1 (ru) * 1989-05-03 1991-11-07 Akhmedzyanov Maksut M Композици дл изготовлени строительных материалов
NZ246606A (en) * 1992-02-07 1995-09-26 Ciba Geigy Ag Antimalarial compostions containing a synergistic combination of benflumetol and quinine or a derivative thereof

Also Published As

Publication number Publication date
US5834505A (en) 1998-11-10
IL129635A (en) 2002-05-23
GB9622427D0 (en) 1997-01-08
EP0938306A1 (de) 1999-09-01
IL129635A0 (en) 2000-02-29
PT938306E (pt) 2002-12-31
AU4788097A (en) 1998-05-22
CA2270138A1 (en) 1998-05-07
NZ335451A (en) 2001-02-23
JP2001507672A (ja) 2001-06-12
AU738885B2 (en) 2001-09-27
DE69715895T2 (de) 2003-07-31
ES2183146T3 (es) 2003-03-16
DE69715895D1 (de) 2002-10-31
EP0938306B1 (de) 2002-09-25
WO1998018462A1 (en) 1998-05-07
DK0938306T3 (da) 2003-01-13
ATE224709T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
Ashley et al. Drugs in Development for Malaria: EA Ashley, AP Phyo
Davis et al. Artemisinin‐based combination therapies for uncomplicated malaria
Kumar et al. Perspective in antimalarial chemotherapy
Schlitzer Antimalarial drugs–what is in use and what is in the pipeline
Cook Prevention and treatment of malaria
Chawira et al. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice
Peters The evolution of tafenoquine—antimalarial for a new millennium?
Peters et al. The chemotherapy of rodent malaria. XLIX. The activities of some synthetic 1, 2, 4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites. Part 2: Structure-activity studies on cis-fused cyclopenteno-1, 2, 4-trioxanes (fenozans) against drug-sensitive and drug-resistant lines of Plasmodium berghei and P. yoelii ssp. NS in vivo
US4260615A (en) Antimalarial compositions
Held et al. Antimalarial compounds in Phase II clinical development
Fernandes et al. Antiprotozoal agents: How have they changed over a decade?
Dormoi et al. Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model
Mital Recent advances in antimalarial compounds and their patents
OA11039A (en) Antimalarial compositions containing cis-fused cyclopenteno-1,2,4-trioxane derivatives
NZ230926A (en) Antimalarial composition comprising artemisinine (or derivatives thereof), quinidine and optionally mefloquine
Kemirembe et al. Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum
HU200688B (en) Process for producing pharmaceutical composition against malaria
Ohrt et al. Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria
Sutherland et al. The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure.
Peters et al. The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, part 2: the new generation—artemisinin or artesunate with long-acting blood schizontocides
KR20080009088A (ko) 말라리아를 치료하기 위한 페로퀸과 아르테미시닌 유도체의복합 제제
JPH02500979A (ja) 抗マラリア組成物および方法
Obaldía III The human malaria-Aotus monkey model: a historical perspective in antimalarial chemotherapy research at the Gorgas Memorial Laboratory-Panama
Dutta et al. Study of the gametocytocidal/sporontocidal action of qinghaosu (artemisinin) by electron microscopy
EP1210116B1 (de) Zusammensetzung zur behandlung von virusinfektionen, die einen calcium-kanal-blocker und ein chinolin enthält